Merck & Co [MRK] vs Gilead Sciences [GILD] Detailed Stock Comparison
Merck & Co
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Merck & Co wins in 16 metrics, Gilead Sciences wins in 4 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Merck & Co | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.73 | 24.41 | Merck & Co |
| Price-to-Book Ratio | 4.30 | 7.34 | Merck & Co |
| Debt-to-Equity Ratio | 71.99 | 130.79 | Merck & Co |
| PEG Ratio | 8.79 | 15.21 | Merck & Co |
| EV/EBITDA | 8.00 | 11.42 | Merck & Co |
| Profit Margin (TTM) | 25.79% | 20.76% | Merck & Co |
| Operating Margin (TTM) | 36.61% | 38.49% | Gilead Sciences |
| EBITDA Margin (TTM) | 36.61% | 38.49% | Gilead Sciences |
| Return on Equity | 36.91% | 32.65% | Merck & Co |
| Return on Assets (TTM) | 14.62% | 12.14% | Merck & Co |
| Free Cash Flow (TTM) | $18.10B | $10.31B | Merck & Co |
| Dividend Yield | 3.01% | 2.84% | Merck & Co |
| 1-Year Return | -29.04% | 49.49% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 3.26 | 5.03 | Merck & Co |
| Enterprise Value | $233.17B | $156.76B | Merck & Co |
| EV/Revenue Ratio | 3.67 | 5.46 | Merck & Co |
| Gross Profit Margin (TTM) | 77.98% | 76.90% | Merck & Co |
| Revenue per Share (TTM) | $25 | $23 | Merck & Co |
| Earnings per Share (Diluted) | $6.49 | $4.63 | Merck & Co |
| Beta (Stock Volatility) | 0.40 | 0.31 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Merck & Co vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Merck & Co | -1.06% | -2.66% | 3.27% | -4.05% | -17.38% | -17.57% |
| Gilead Sciences | 0.46% | 1.06% | 3.51% | 7.72% | 18.37% | 24.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Merck & Co | -29.04% | -6.48% | 5.74% | 47.80% | 145.13% | 179.58% |
| Gilead Sciences | 49.49% | 87.85% | 65.48% | 0.28% | 540.76% | 976.55% |
Performance & Financial Health Analysis: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $207.49B | $144.55B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 12,483,860 | 5,024,069 |
| 90 Day Avg. Volume | 16,084,237 | 7,151,096 |
| Last Close | $81.75 | $114.76 |
| 52 Week Range | $73.31 - $123.94 | $72.43 - $119.96 |
| % from 52W High | -34.04% | -4.33% |
| All-Time High | $134.63 (Jun 24, 2024) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -39.28% | -6.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.00% |
| Quarterly Earnings Growth | -0.19% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.21% |
| Operating Margin (TTM) | 0.37% | 0.38% |
| Return on Equity (TTM) | 0.37% | 0.33% |
| Debt to Equity (MRQ) | 71.99 | 130.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.21 | $15.39 |
| Cash per Share (MRQ) | $3.68 | $7.00 |
| Operating Cash Flow (TTM) | $22.75B | $10.37B |
| Levered Free Cash Flow (TTM) | $17.12B | $9.99B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.01% | 2.84% |
| Last 12-Month Dividend | $2.39 | $3.12 |
Valuation & Enterprise Metrics Analysis: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.73 | 24.41 |
| Forward P/E | 8.79 | 15.21 |
| PEG Ratio | 8.79 | 15.21 |
| Price to Sales (TTM) | 3.26 | 5.03 |
| Price to Book (MRQ) | 4.30 | 7.34 |
| Market Capitalization | ||
| Market Capitalization | $207.49B | $144.55B |
| Enterprise Value | $233.17B | $156.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.67 | 5.46 |
| Enterprise to EBITDA | 8.00 | 11.42 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.31 |
| Book Value per Share (MRQ) | $19.21 | $15.39 |
Financial Statements Comparison: Merck & Co vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Revenue/Sales | $15.53B | $6.67B |
| Cost of Goods Sold | $3.42B | $1.54B |
| Gross Profit | $12.11B | $5.13B |
| Research & Development | $3.62B | $1.38B |
| Operating Income (EBIT) | $5.94B | $2.49B |
| EBITDA | $7.38B | $3.28B |
| Pre-Tax Income | $5.90B | $1.65B |
| Income Tax | $818.00M | $334.00M |
| Net Income (Profit) | $5.09B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Cash & Equivalents | $8.63B | $7.93B |
| Total Current Assets | $35.50B | $16.90B |
| Total Current Liabilities | $25.17B | $12.34B |
| Long-Term Debt | $33.48B | $22.15B |
| Total Shareholders Equity | $48.40B | $19.08B |
| Retained Earnings | $66.10B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Operating Cash Flow | $6.30B | $1.56B |
| Capital Expenditures | N/A | $-104.00M |
| Free Cash Flow | $1.17B | $1.65B |
| Debt Repayment | $-2.50B | $-1.76B |
| Common Stock Repurchase | $-1.16B | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | MRK | GILD |
|---|---|---|
| Shares Short | 28.77M | 22.54M |
| Short Ratio | 1.61 | 2.80 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 12,483,860 | 5,024,069 |
| Average Daily Volume (90 Day) | 16,084,237 | 7,151,096 |
| Shares Outstanding | 2.53B | 1.25B |
| Float Shares | 2.51B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.81% | 0.90% |
Dividend Analysis & Yield Comparison: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Last 12-Month Dividend | $2.39 | $3.12 |
| Last 12-Month Dividend Yield | 3.01% | 2.84% |
| 3-Year Avg Annual Dividend | $2.77 | $3.04 |
| 3-Year Avg Dividend Yield | 0.71% | 0.93% |
| 3-Year Total Dividends | $8.31 | $9.12 |
| Ex-Dividend Date | Mar 17, 2025 | Jun 13, 2025 |